Antibody-dependent Cellular Cytotoxicity of Cetuximab Against Tumor Cells with Wild-type or Mutant Epidermal Growth Factor Receptor

Overview

Journal Cancer Sci

Specialty Oncology

Date 2007 May 15

PMID 17498200

Citations 106

Authors

Hideharu Kimura

Kazuko Sakai

Tokuzo Arao

Tatsu Shimoyama

Tomohide Tamura

Kazuto Nishio

Affiliations

Soon will be listed here.

Abstract

Cetuximab (Erbitux, IMC-C225) is a monoclonal antibody targeted to the epidermal growth factor receptor (EGFR). To clarify the mode of antitumor action of cetuximab, we examined antibody-dependent cellular cytotoxicity (ADCC) activity against several tumor cell lines expressing wild-type or mutant EGFR. ADCC activity and complement-dependent cytolysis activity were analyzed using the CytoTox 96 assay. ADCC activities correlated with the EGFR expression value (R = 0.924). ADCC activities were detected against all tumor cell lines, except K562 cells in a manner dependent on the cellular EGFR expression level, whereas complement-dependent cytolysis activity was not detected in any of the cell lines. The ADCC activity mediated by cetuximab was examined in HEK293 cells transfected with wild-type EGFR (293W) and a deletional mutant of EGFR (293D) in comparison with the mock transfectant (293M). ADCC activity was detected in 293W and 293D cells, in a cetuximab dose-dependent manner, but not in 293M cells (<10%). These results indicate that ADCC-dependent antitumor activity results from the degree of affinity of cetuximab for the extracellular domain of EGFR, independent of EGFR mutation status. These results suggest ADCC activity to be one of the modes of therapeutic action of cetuximab and to depend on EGFR expression on the tumor cell surface.

Citing Articles

Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients.

Schiele P, Kolling S, Rosnev S, Junkuhn C, Walter A, von Einem J Cells. 2025; 14(1.

PMID: 39791733 PMC: 11720420. DOI: 10.3390/cells14010032.

Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions.

McKeague M, Lohmueller J, Dracz M, Saadallah N, Ricci E, Beckwith D Antibodies (Basel). 2024; 13(4.

PMID: 39449327 PMC: 11503386. DOI: 10.3390/antib13040085.

Safety switch optimization enhances antibody-mediated elimination of CAR T cells.

Shabaneh T, Moffett H, Stull S, Derezes T, Tait L, Park S Front Mol Med. 2024; 2:1026474.

PMID: 39086975 PMC: 11285702. DOI: 10.3389/fmmed.2022.1026474.

The Agonistic Activity of the Human Epidermal Growth Factor is Reduced by the D46G Substitution.

Akunevich A, Khrustalev V, Khrustaleva T, Yermalovich M Protein Pept Lett. 2024; 31(7):504-518.

PMID: 39041280 DOI: 10.2174/0109298665297321240708044223.

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.

Frigault M, Graham C, Berger T, Ritchey J, Horick N, El-Jawahri A Blood. 2024; 144(11):1153-1167.

PMID: 38781564 PMC: 11830985. DOI: 10.1182/blood.2024024104.

References

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001; 37 Suppl 1:S25-9. View

Mendelsohn J . Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1999; 3(12 Pt 2):2703-7. View

Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P . Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2003; 15(1):28-32. DOI: 10.1093/annonc/mdh011. View

de Bono J, Rowinsky E . The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med. 2002; 8(4 Suppl):S19-26. DOI: 10.1016/s1471-4914(02)02306-7. View

Grillo-Lopez A, White C, Varns C, Shen D, Wei A, McClure A . Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999; 26(5 Suppl 14):66-73. View

Naruse I, Fukumoto H, Saijo N, Nishio K . Enhanced anti-tumor effect of trastuzumab in combination with cisplatin. Jpn J Cancer Res. 2002; 93(5):574-81. PMC: 5927030. DOI: 10.1111/j.1349-7006.2002.tb01293.x. View

Bianco R, Daniele G, Ciardiello F, Tortora G . Monoclonal antibodies targeting the epidermal growth factor receptor. Curr Drug Targets. 2005; 6(3):275-87. DOI: 10.2174/1389450053765842. View

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

10.

Carson W, Parihar R, Lindemann M, Personeni N, Dierksheide J, Meropol N . Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol. 2001; 31(10):3016-25. DOI: 10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j. View

11.

Hale G, Zhang M, Bunjes D, Prentice H, Spence D, Horowitz M . Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998; 92(12):4581-90. View

12.

Nagai Y, Miyazawa H, Huqun , Tanaka T, Udagawa K, Kato M . Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005; 65(16):7276-82. DOI: 10.1158/0008-5472.CAN-05-0331. View

13.

DallOzzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P . Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004; 64(13):4664-9. DOI: 10.1158/0008-5472.CAN-03-2862. View

14.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

15.

Mukohara T, Engelman J, Hanna N, Yeap B, Kobayashi S, Lindeman N . Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005; 97(16):1185-94. DOI: 10.1093/jnci/dji238. View

16.

Mendelsohn J . Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res. 2000; 6(3):747-53. View

17.

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

18.

Graziano R, Fanger M . Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. J Immunol. 1987; 139(10):3536-41. View

19.

Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M . The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2002; 278(5):3466-73. DOI: 10.1074/jbc.M210665200. View

20.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View